A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase

Publication | Closed Access

DOI

Citations

References

2014

Year

Gregory M. Pastores, Мilan Petakov, Pilar Giraldo, Hanna Rosenbaum, Patrick Deegan, Dominick Amato, Eugen Mengel, Ee Shien Tan, Raul Chertkoff, Einat Brill‐Almon,

Blood Cells Molecules and Diseases

Phase 3Switchover TrialPlant PathologySubstrate Reduction TherapyMedicineLysosomal Storage DiseaseTaliglucerase Alfa